<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04706130</url>
  </required_header>
  <id_info>
    <org_study_id>20-0010</org_study_id>
    <nct_id>NCT04706130</nct_id>
  </id_info>
  <brief_title>Rigorous Assessment of P. Vivax Relapses and Primaquine Efficacy for Radical Cure</brief_title>
  <official_title>Rigorous Assessment of P. Vivax Relapses and Primaquine Efficacy for Radical Cure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cambodian National Centre for Parasitology Entomology and Malaria Control</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Pasteur du Cambodge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be an open-labelled randomized clinical trial to determine therapeutic&#xD;
      efficacy. Note that this will not be an Investigational New Drug application, as only&#xD;
      WHO-approved drugs will be used at dosage and for conditions approved.&#xD;
&#xD;
      Eligible patients willing to participate will first be tested prior to enrolment for their&#xD;
      G6PD status by the gold standard spectrophotometric analysis. The investigators will exclude&#xD;
      from the study any G6PD deficient (or intermediate females) patient. Treatment allocation&#xD;
      will be randomized between i) 7 days of artesunate (2 mg/kg/day for 7 days) alone (Arm1), ii)&#xD;
      same artesunate regimen + 0.25 mg/kg/day 14 days of primaquine (Arm2) and iii) same&#xD;
      artesunate regimen + 0.5 mg/kg/day 14 days of primaquine (Arm3). All patients will be&#xD;
      relocated to a no-transmission city (Chbar Mon) to make sure they are not reinfected during&#xD;
      the follow-up. Follow-up will be performed every 24-48h for 90 days. At the end of the&#xD;
      follow-up period, all patients that did not receive primaquine (arm1) will be treated&#xD;
      according to national guidelines (14 days at 0.25mg/kg/day). Patients will additionally be&#xD;
      followed monthly for three months after the end of the relocation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2021</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study will be an open-labelled randomized clinical trial to determine therapeutic efficacy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>P. vivax recurrence</measure>
    <time_frame>3 months</time_frame>
    <description>Proportion of patients experiencing recurrence as measured by microscopy and PCR and time to recurrence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Markers of P. vivax recurrences</measure>
    <time_frame>3 months</time_frame>
    <description>Gene expression or serological markers associated with P. vivax recurrence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Genotypes of relapsing P. vivax parasites</measure>
    <time_frame>3 months</time_frame>
    <description>Genotypes of relapsing P. vivax parasites</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Vivax Malaria</condition>
  <arm_group>
    <arm_group_label>Arm1: No primaquine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Enrolled patients will only received blood stage antimalarial (artesunate at 2 mg/kg per day every 24h for 7 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm2: Primaquine low dose</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Enrolled patients will received blood stage antimalarial (artesunate at 2 mg/kg per day every 24h for 7 days) and primaquine at 0.25 mg/kg/day for 14 days (starting at day 7)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm3: Primaquine high dose</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Enrolled patients will received blood stage antimalarial (artesunate at 2 mg/kg per day every 24h for 7 days) and primaquine at 0.50 mg/kg/day for 14 days (starting at day 7)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Primaquine</intervention_name>
    <description>After treatment of the blood stage infection, enrolled participants will receive either no primaquine, a low dose of primaquine or a high dose of primaquine against liver parasites</description>
    <arm_group_label>Arm2: Primaquine low dose</arm_group_label>
    <arm_group_label>Arm3: Primaquine high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artesunate</intervention_name>
    <description>All enrolled participants will receive a 7-day treatment of artesunate ((2 mg/kg/day) to clear blood-stage parasites</description>
    <arm_group_label>Arm1: No primaquine</arm_group_label>
    <arm_group_label>Arm2: Primaquine low dose</arm_group_label>
    <arm_group_label>Arm3: Primaquine high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 15 and older&#xD;
&#xD;
          -  Acute (within 10 days), symptomatic (i.e., history of fever), uncomplicated malaria&#xD;
             caused solely by Plasmodium vivax (verified by PCR)&#xD;
&#xD;
          -  G6PD normal (as determined by quantitative spectrophotometric assay)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant, planning to become pregnant or lactating women,&#xD;
&#xD;
          -  Received antimalarial drugs in the past month,&#xD;
&#xD;
          -  Hb &lt; 8g/dL, &lt; 1,500 neutrophils/μl, or signs of complicated malaria (e.g., vomiting,&#xD;
             convulsions,…),&#xD;
&#xD;
          -  History of primaquine, artesunate or artesunate-mefloquine allergy or intolerance,&#xD;
&#xD;
          -  PCR-positivity for SARS-CoV-2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut Pasteur du Cambodge</name>
      <address>
        <city>Phnom Penh</city>
        <country>Cambodia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Popovici, Ph.D.</last_name>
      <phone>089 851 806</phone>
      <email>jpopovici@pasteur-kh.org</email>
    </contact>
    <investigator>
      <last_name>Jean Popovici, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benoit Witkowski, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Cambodia</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 8, 2021</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>David Serre</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria, Vivax</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Primaquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

